Structure of Nucleotide binding domain of HSP110, ATP and Mg2+ complexed

Experimental Data Snapshot

  • Resolution: 2.00 Å
  • R-Value Free: 0.229 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.189 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.4 of the entry. See complete history


Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy.

Gozzi, G.J.Gonzalez, D.Boudesco, C.Dias, A.M.M.Gotthard, G.Uyanik, B.Dondaine, L.Marcion, G.Hermetet, F.Denis, C.Hardy, L.Suzanne, P.Douhard, R.Jego, G.Dubrez, L.Demidov, O.N.Neiers, F.Briand, L.Sopkova-de Oliveira Santos, J.Voisin-Chiret, A.S.Garrido, C.

(2020) Cell Death Differ 27: 117-129

  • DOI: https://doi.org/10.1038/s41418-019-0343-4
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    Pro-survival stress-inducible chaperone HSP110 is the only HSP for which a mutation has been found in a cancer. Multicenter clinical studies demonstrated a direct association between HSP110 inactivating mutation presence and excellent prognosis in colorectal cancer patients. Here, we have combined crystallographic studies on human HSP110 and in silico modeling to identify HSP110 inhibitors that could be used in colorectal cancer therapy. Two molecules (foldamers 33 and 52), binding to the same cleft of HSP110 nucleotide-binding domain, were selected from a chemical library (by co-immunoprecipitation, AlphaScreening, Interference-Biolayer, Duo-link). These molecules block HSP110 chaperone anti-aggregation activity and HSP110 association to its client protein STAT3, thereby inhibiting STAT3 phosphorylation and colorectal cancer cell growth. These effects were strongly decreased in HSP110 knockdown cells. Foldamer's 33 ability to inhibit tumor growth was confirmed in two colorectal cancer animal models. Although tumor cell death (apoptosis) was noted after treatment of the animals with foldamer 33, no apparent toxicity was observed, notably in epithelial cells from intestinal crypts. Taken together, we identified the first HSP110 inhibitor, a possible drug-candidate for colorectal cancer patients whose unfavorable outcome is associated to HSP110.

  • Organizational Affiliation

    INSERM UMR1231, Laboratory of Excellence LipSTIC and label Ligue Nationale contre le Cancer, Dijon, France.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Heat shock protein 105 kDa381Homo sapiensMutation(s): 0 
Gene Names: HSPH1HSP105HSP110KIAA0201
UniProt & NIH Common Fund Data Resources
Find proteins for Q92598 (Homo sapiens)
Explore Q92598 
Go to UniProtKB:  Q92598
PHAROS:  Q92598
GTEx:  ENSG00000120694 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ92598
Sequence Annotations
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Resolution: 2.00 Å
  • R-Value Free: 0.229 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.189 
  • Space Group: P 61 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 109.78α = 90
b = 109.78β = 90
c = 144.22γ = 120
Software Package:
Software NamePurpose
XDSdata reduction
XSCALEdata scaling
ARP/wARPmodel building

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2019-05-08
    Type: Initial release
  • Version 1.1: 2019-07-03
    Changes: Data collection, Database references
  • Version 1.2: 2019-10-16
    Changes: Data collection
  • Version 1.3: 2019-12-25
    Changes: Database references
  • Version 1.4: 2024-01-17
    Changes: Advisory, Data collection, Database references, Derived calculations, Refinement description